Vancomycin-Induced Changes in Host Immunity and Behavior: Comparative Genomic and Metagenomic Analysis in C57BL/6 and BALB/c Mice

Dig Dis Sci. 2021 Nov;66(11):3776-3791. doi: 10.1007/s10620-020-06729-x. Epub 2021 Jan 1.

Abstract

Background: The consequence of treatment with antibiotics on the gut microbiota can be destructive. The antibiotics, however, can be utilized to understand the role of gut microbiota on the host physiology.

Aim: Earlier, we reported the efficacy of vancomycin in gut microbiota perturbation. We continued to understand the effect of restoration kinetics of perturbed gut microbiota on the immunity and behavior of Th1 (C57BL/6)- and Th2 (BALB/c)-biased mice.

Methods: We studied restoration kinetics of the gut microbiota for two months following the withdrawal of vancomycin treatment in both mice strains. We analyzed cecal microbiome composition, different behavioral assays, and expression of select genes associated with stress and barrier function in gut and brain.

Results: Metagenomic analysis of gut microbiota revealed that the treatment with vancomycin caused a significant decrease in the relative abundance of Firmicutes and Bacteroidetes phyla with a time-dependent increase in Proteobacteria and Verrucomicrobia phyla. Maximum restoration (> 70%) of gut microbiota happened by the 15th day of withdrawal of vancomycin. BALB/c mice showed a more efficient restoration of gut microbiota compared to C57BL/6 mice. We established the correlation patterns of gut microbiota alteration and its effect on (a) the behavior of mice, (b) expression of key brain molecules, and (c) immunity-related genes.

Conclusions: The results revealed that the gut microbiome profiling, behavior, and immune responses varied significantly between Th1- and Th2-biased mice. By withdrawing the treatment with vancomycin of major gut microbes, important physiological and behavioral changes of both mice strains returned to the normal (untreated control) level.

Keywords: Anxiety; Brain; Depression; Gut microbiota; Inflammation; Vancomycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Behavior, Animal
  • DNA, Bacterial
  • Gastrointestinal Microbiome / drug effects*
  • Gene Expression Regulation / drug effects
  • Genomics
  • Immunity / drug effects*
  • Male
  • Metagenomics
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • RNA, Bacterial
  • RNA, Ribosomal, 16S
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial
  • RNA, Bacterial
  • RNA, Ribosomal, 16S
  • Vancomycin